Day 2: Wednesday 8th February 2017

Mr Adam Levysohn
09:00

Chairman’s opening remarks

Mr Adam Levysohn, Head of Global Market Access Biogen Biosimilars Business Unit, Biogen
Ismail Bel Bachir
09:10

Managing a pharmaceutical business in MENA through turbulent times

Ismail Bel Bachir, CEO, Tabuk Pharmaceuticals
Dr Konji Sebati
09:50

The role of The role of research-based pharmaceutical companies in ensuring affordable medicines

Dr Konji Sebati, Chief Executive Officer, Innovative Pharmaceutical Association
Post launch strategies for biosimilars
10:10

'Unlocking the value of Biosimilars' - The market access perspective

Mr Adam Levysohn, Head of Global Market Access Biogen Biosimilars Business Unit, Biogen
Tommy Erdei
10:30

Overview of the global market: Trends and opportunities

Tommy Erdei, Global Joint Head of Pharmaceuticals and Life Sciences, Joint Head of European Healthcare Investment Banking,, Jefferies Group
10:50

Morning coffee, speed networking and poster viewing

Panel discussion
11:30

Roundtable 1: Industry strategy (Generics)

Frances Cloud, Founder, Pharmacloud Ltd
Panel discussion
11:30

Roundtable 2: Development challenges of biosimilars

Mr Patrick Liu, Vice President of Global Biologics R&D and Head of Biologics, Assays and Technology, Teva Pharmaceuticals U.S.A.
11:30

Roundtable 3:Can Generic manufacturers be cost competitive with European Production?

Mr Paul Mendelsohn, Chief Executive Officer, Pharmawise Ltd
11:30

Roundtable 4: IP Strategy (Biosimilars)

12:20

Lunch

New market and new business models
13:20

Intro: New markets and new business models

Mr Rajaram Iyer, Vice President-Business Development and Portfolio, MANKIND PHARMA LTD
Biosimilars - clinical challenges
13:20

Intro: Biosimilars - clinical challenges

Mr Anjan Selz, Vice President – Head of Biosimilars EMEA, Lupin Europe Ltd
New market and new business models
13:25

Industry trend for 2017

Mr Raul Diaz-Varela, Deputy Chairman of the Indukern Group and CEO, Kern Pharma
Biosimilars - clinical challenges
13:25

Which study design and data do we need to demonstrate bioequivalence? A global perspective

Mr Pavel Farkas, Senior Director Biopharmaceutics/Clinical Development, Pliva
New market and new business models
13:45

Capitalising on market opportunities - differentiated business models

Mrs Erika Geimonen, Vice President, Business Development, Amring Pharmaceuticals
Biosimilars - clinical challenges
13:45

Developing an integrated approach to biosimilar development and commercialization

Mr Darius Panaligan, Vice President, Global Head of Commercial, Merck Biosimilars
New market and new business models
14:05

Specialty generics

Mr Rajaram Iyer, Vice President-Business Development and Portfolio, MANKIND PHARMA LTD
Biosimilars - clinical challenges
14:05

Addressing the immunogenicity issues for biosimilars

Mr Patrick Liu, Vice President of Global Biologics R&D and Head of Biologics, Assays and Technology, Teva Pharmaceuticals U.S.A.
New market and new business models
14:25

Q&A with session speakers

Biosimilars - clinical challenges
14:25

Q&A with session speakers

14:40

Afternoon refreshments and exhibition viewing

Post launch strategies for biosimilars
15:10

Intro: Post launch strategies for biosimilars

Mr Pavel Farkas, Senior Director Biopharmaceutics/Clinical Development, Pliva
Post launch strategies for biosimilars
15:15

Long term growth strategies for biosimilars

Mr Anjan Selz, Vice President – Head of Biosimilars EMEA, Lupin Europe Ltd
Post launch strategies for biosimilars
15:35

Demonstrating comparability in the real world

Mr Matthew Turner, Medical Director, Merck Group
Post launch strategies for biosimilars
15:55

Post launch safety monitoring or biosimilars

Mr Bernd Liedert, Senior director biosimilars, Boehringer Ingelheim Pharma Co Gmbh
Post launch strategies for biosimilars
16:35

Q&A with session speakers

Post launch strategies for biosimilars
16:50

Closing remarks from the chair

Mr Pavel Farkas, Senior Director Biopharmaceutics/Clinical Development, Pliva
17:00

End of the conference

last published: 03/Feb/17 14:45 GMT
BOOK NOW